ArQule Gets Early-Stage Cancer Program Back From Daiichi
This article was originally published in The Pink Sheet Daily
The Japanese pharma has elected to return rights to an early-stage cancer development program to ArQule, but the biotech reassured investors the two companies will continue to move forward on their beleaguered late-stage oncology endeavor.
You may also be interested in...
Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.
ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
Progression-free survival benefit fails to translate into overall survival in Phase III NSCLC study of c-Met inhibitor tivantinib, partnered with Daiichi Sankyo. ArQule shifts focus to an imminent, targeted second-line Phase III study of high-Met expressing hepatocellular cancer.
ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi-Sankyo
Two deals bring the biotech $75 million upfront, plus research and clinical development funding.